We are live on ! Find out more
IOBT

IO Biotech
IOBT

Delisted

IOBT was delisted on the 6th of April, 2026.

Back to rankings

12 hedge funds and large institutions have $199K invested in IO Biotech in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

6.19% less ownership

Funds ownership: 10.91% → 4.71% (-6.2%)

45% less funds holding

Funds holding: 22 → 12 (-10)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

96% less capital invested

Capital invested by funds: $4.78M → $199K (-$4.58M)

Holders
12
Holders Change
-10
Holders Change %
-45.45%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
5
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$119K
2
XT
XTX Topco
Cayman Islands
+$85.3K
3
Jane Street
Jane Street
New York
+$19.8K
4
Millennium Management
Millennium Management
New York
+$18.9K

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$1.53M
2
Bank of America
Bank of America
North Carolina
-$486K
3
DIG
Dauntless Investment Group
New Hampshire
-$275K
4
BPA
Beacon Pointe Advisors
California
-$158K
5
Renaissance Technologies
Renaissance Technologies
New York
-$126K

IOBT Hedge Fund Activity: Q1 2026 in Review

12 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q1 2026, worth a combined $199K — down 96% from $4.78M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of IOBT and 2 opened new positions — a net loss of 10 holders — while 5 trimmed existing stakes and 2 added.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $119K. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $1.53M sold.

  • 12 institutional investors held IO Biotech (IOBT) as of Q1 2026, down from 22 in Q4 2025.
  • Funds reported $199K of IO Biotech stock for Q1 2026, down 96% quarter-over-quarter.
  • 2 funds opened new IO Biotech positions in Q1 2026 and 12 closed out, a net change of -10 holders.
  • The largest IO Biotech buyer in Q1 2026 was GSA Capital Partners, an estimated $119K added.
  • The largest IO Biotech seller in Q1 2026 was Novo Holdings A/S, an estimated $1.53M sold.

Based on aggregated 13F filings for Q1 2026.